Subsequent therapy following pembrolizumab plus axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study

被引：4

作者：

Gafanov, R. ^{[1
]}

Powles, T. B. ^{[2
,3
,4
]}

Bedke, J. ^{[5
]}

Stus, V. ^{[6
]}

Waddell, T. S. ^{[7
]}

Nosov, D. ^{[8
]}

Pouliot, F. ^{[9
,10
]}

Soulieres, D. ^{[11
]}

Melichar, B. ^{[12
,13
]}

Azevedo, S. ^{[14
]}

McDermott, R. S. ^{[15
,16
]}

Vynnychenko, I. O. ^{[17
]}

Borchiellini, D. ^{[18
]}

Markus, M. ^{[19
]}

Bondarenko, I. ^{[5
]}

Lin, J. ^{[20
]}

Burgents, J. ^{[20
]}

Molife, L. R. ^{[19
,21
]}

Plimack, E. R. ^{[22
]}

Rini, B. ^{[23
]}

机构：

[1] Russian Sci Ctr Roentgenoradiol, Urol, Moscow, Russia

[2] Barts Hlth NHS Trust, Dept Genitourinary Oncol, London, England

[3] Royal Free NHS Fdn Trust, Barts Canc Inst, London, England

[4] Queen Mary Univ London, London, England

[5] Eberhard Karls Univ Tubingen, Urol, Tubingen, Germany

[6] Minist Hlth Ukraine, Urol, Dnipropetrovsk Med Acad, Dnipro, Ukraine

[7] Christie NHS Fdn Trust, Med Oncol, Manchester, Lancs, England

[8] Cent Clin Hosp, Oncol, Outpatient Clin, Moscow, Russia

[9] CHU Quebec, Surg, Quebec City, PQ, Canada

[10] Laval Univ, Quebec City, PQ, Canada

[11] Ctr Hosp Univ Montreal, Hematol Oncol, Montreal, PQ, Canada

[12] Palacky Univ, Med Sch, Olomouc, Czech Republic

[13] Teaching Hosp, Olomouc, Czech Republic

[14] Hosp Clin Porto Alegre, Oncol, Porto Alegre, RS, Brazil

[15] Adelaide & Meath Hosp, Hematol Oncol, Dublin, Ireland

[16] Univ Coll Dublin, Dublin, Ireland

[17] Sumy State Univ, Sumy Reg Oncol Ctr, Surg & Oncol, Sumy, Ukraine

[18] Univ Cote dAzur, Ctr Antoine Lacassagne, Med Oncol, Nice, France

[19] Rocky Mt Canc Ctr, Med Oncol, Colorado Springs, CO USA

[20] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[21] MSD UK, Med Oncol, London, England

[22] Fox Chase Canc Ctr, Genitourinary Med Oncol, Philadelphia, PA USA

[23] Vanderbilt Ingram Canc Ctr, Med Oncol, Nashville, TN USA

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.065

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

669P

引用

页码：S694 / S694

页数：1

共 50 条

[1] Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC)
Rini, Brian I.
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem
Waddell, Tom
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris
Soulieres, Denis
Azevedo, Sergio Jobim
Borchiellini, Delphine
McDermott, Raymond S.
Perini, Rodolfo F.
Markensohn, Julia
Molife, L. Rhoda
Zhang, Yiwei
Nebozhyn, Michael
Loboda, Andrey
Vajdi, Amir
Powles, Thomas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Outcomes for patients in the pembrolizumab plus axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.
Plimack, Elizabeth R.
Powles, Thomas
Bedke, Jens
Pouliot, Frederic
Stus, Viktor
Waddell, Tom
Gafanov, Rustem
Nosov, Dmitry
Alekseev, Boris
McDermott, Raymond S.
Markus, Maurice
Tartas, Sophie
Kryzhanivska, Anna
Bondarenko, Igor
Szczylik, Cezary
Lin Jianxin
Perini, Rodolfo F.
Molife, Rhoda L.
Atkins, Michael B.
Rini, Brian, I
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[3] KEYNOTE-426 Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma
Bedke, J.
Stuehler, V.
[J]. UROLOGE, 2020, 59 (07): : 841 - 842
[4] Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC)
Rini, Brian I.
Powles, Thomas
Chen, Mei
Puhlmann, Markus
Atkins, Michael B.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
Plimack, Elizabeth R.
Rini, Brian, I
Stus, Viktor
Gafanov, Rustem
Waddell, Tom
Nosov, Dmitry
Pouliot, Frederic
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor
Azevedo, Sergio Jobim
Borchiellini, Delphine
McDermott, Raymond S.
Bedke, Jens
Tamada, Satoshi
Yin, Lina
Chen, Mei
Molife, L. Rhoda
Atkins, Michael B.
Powles, Thomas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma
Bedke, Jens
Rini, Brian, I
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem
Waddell, Tom
Nosov, Dimitry
Pouliot, Frederic
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor
Azevedo, Sergio J.
Borchiellini, Delphine
McDermott, Raymond S.
Tamada, Satoshi
Nguyen, Allison Martin
Wan, Shuyan
Perini, Rodolfo F.
Molife, L. Rhoda
Atkins, Michael B.
Powles, Thomas
[J]. EUROPEAN UROLOGY, 2022, 82 (04) : 427 - 439
[7] Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426
Rini, Brian I.
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem
Waddell, Tom
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor O.
Azevedo, Sergio Jobim
Borchiellini, Delphine
McDermott, Raymond S.
Bedke, Jens
Tamada, Satoshi
Wu, Sterling
Burgents, Joseph
Molife, L. Rhoda
Powles, Thomas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[8] Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
Tamada, Satoshi
Kondoh, Chihiro
Matsubara, Nobuaki
Mizuno, Ryuichi
Kimura, Go
Anai, Satoshi
Tomita, Yoshihiko
Oyama, Masafumi
Masumori, Naoya
Kojima, Takahiro
Matsumoto, Hiroaki
Chen, Mei
Li, Mengran
Matsuda, Kenji
Tanaka, Yoshinobu
Rini, Brian, I
Uemura, Hirotsugu
[J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 154 - 164
[9] Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
Satoshi Tamada
Chihiro Kondoh
Nobuaki Matsubara
Ryuichi Mizuno
Go Kimura
Satoshi Anai
Yoshihiko Tomita
Masafumi Oyama
Naoya Masumori
Takahiro Kojima
Hiroaki Matsumoto
Mei Chen
Mengran Li
Kenji Matsuda
Yoshinobu Tanaka
Brian I. Rini
Hirotsugu Uemura
[J]. International Journal of Clinical Oncology, 2022, 27 : 154 - 164
[10] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study.
Powles, Thomas
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem Airatovich
Hawkins, Robert E.
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris Yakovlevich
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor
Kryzhanivska, Anna
Bondarenko, Igor
Azevedo, Sergio Jobim
Borchiellini, Delphine
Shou, Qiong
Perini, Rodolfo F.
Chen, Mei
Atkins, Michael B.
Rini, Brian I.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)

← 1 2 3 4 5 →